Ovarian cancer cell

Ovarian cancer cells are malignant cells that originate in the ovaries, fallopian tubes, or the peritoneum, with epithelial ovarian carcinoma being the most common histological type (NCI, 2023). These cells are characterized by significant genomic instability, rapid division, and a unique ability to disseminate throughout the abdominal cavity via the peritoneal fluid (NIH, 2024). Although the term 'Ovarian cancer cell' describes a biological entity or disease state rather than a single molecular target, these cells express a variety of targetable proteins and receptors, such as Folate Receptor alpha (FRα), Mucin 16 (CA-125), and Vascular Endothelial Growth Factor (VEGF) (PubMed, 2023). Therapeutic strategies typically focus on eliminating these cells through surgical debulking followed by systemic therapies including DNA-damaging chemotherapy or targeted biological inhibitors. However, the high degree of clonal heterogeneity within these cell populations often leads to the development of multi-drug resistance, which remains the primary challenge in long-term clinical management (Nature Reviews Cancer, 2022).

Other names

Ovarian carcinoma cellOvarian tumor cellMalignant ovarian cellOvarian adenocarcinoma cell

Pharmacological agents targeting ovarian cancer cells utilize diverse mechanisms: platinum-based agents induce DNA cross-linking to prevent replication; taxanes stabilize microtubules to arrest the cell cycle; PARP inhibitors exploit synthetic lethality in cells with BRCA mutations; and antibody-drug conjugates (ADCs) deliver cytotoxic payloads by targeting surface antigens such as Folate Receptor alpha (StatPearls, 2023).